In Law360, Washington Attorneys Examine FDA & FTC Biosimilar Initiatives

In The News
February 20, 2020

The U.S. Food and Drug Administration and the Federal Trade Commission recently announced a collaboration to promote biosimilar competition. In a Law360 article published on Feb 19, life sciences regulatory and compliance partner Kellie Combs (Washington, D.C.) examines key aspects of the FDA/FTC collaboration and related FDA draft guidance regarding promotion of biologics and biosimilars, including implications for the biotechnology and life sciences industry.